FLT3 and acute myeloid leukemia: This mini-review summarizes the growing evidence supporting a role for CPX-351 in the treatment of AML associated with mutations in FLT3. Furthermore, preliminary data from clinical trials and patient case reports suggest that the combination of CPX-351 + midostaurin may represent an additional treatment option for patients with FLT3 mutation-positive AML.